Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary XXXX .

@entity1 @entity5 @entity16 @entity149 @entity10017 @entity14
BACKGROUND: @entity149 ( @entity149 ) are highly aggressive @entity5 . Chemotherapy has improved prognosis significantly; however, early diagnosis is crucial for effective treatment. Presently, the diagnosis of PCNSL depends on histopathology of @entity5 biopsies. We have previously demonstrated differential expression of microRNAs in cerebrospinal fluid (CSF) samples from @entity1 with PCNSL. Based on promising findings about circulating U2 small nuclear RNA fragments (RNU2-1f) as novel blood-based biomarkers for @entity14 , we investigated RNU2-1f in the CSF of PCNSL @entity1 . METHODS: CSF was collected from @entity1 with PCNSL (n = 72) and control @entity1 with various @entity16 (n = 47). Sequential CSF samples were collected from 9 PCNSL @entity1 . RNU2-1f levels were measured by real-time polymerase chain reaction. RESULTS: Measurement of RNU2-1f levels in CSF enabled the differentiation of @entity1 with PCNSL from controls with an area under the curve (AUC) of 0.909 with a sensitivity of 68.1% and a specificity of 91.4%. The diagnostic accuracy was further improved by combined determination of RNU2-1f and @entity10017 , resulting in AUC of 0.987 with a sensitivity of 91.7% and a specificity of 95.7%. In consecutive measurements of RNU2-1f, which were performed in 9 @entity1 at different stages of the disease course, RNU2-1f CSF levels paralleled the course of the disease. CONCLUSIONS: Our data suggest that the measurement of RNU2-1f detected in CSF can be used as a diagnostic marker and also as a possible marker for treatment monitoring. These promising results need to be evaluated within a larger @entity1 cohort.
